Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis - 10/11/18
Abstract |
Background |
Sonic hedgehog inhibitors (SHHis) provide an additional treatment option for basal cell carcinomas (BCCs), especially for metastatic or locally advanced BCC. However, studies have been heterogeneous and lacked direct comparisons between molecules.
Objective |
To determine the efficacy and safety of the class of molecules SHHi for treating BCC and to compare them individually.
Methods |
We performed a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)–compliant systematic review of studies followed by a meta-analysis.
Results |
Eighteen articles were included in our meta-analysis; 16 articles were combined for efficacy and 16 for safety. In locally advanced BCC, overall response rates (ORRs) were similar for vismodegib and sonidegib (69% vs 57%, respectively) but not complete response rates (31% vs 3%, respectively). In metastatic disease, the ORR of vismodegib was 2.7-fold higher than the ORR of sonidegib (39% vs 15%, respectively). For side effects affecting a majority of patients, prevalences for muscle spasms (67.1%), dysgeusia (54.1%), and alopecia (57.7%) were in similar proportions for sonidegib and vismodegib. Patients receiving sonidegib experienced more upper gastrointestinal distress than patients receiving vismodegib.
Conclusion |
SHHis induce a partial response to locally advanced BCC disease. Side effects are common, similar across molecules, associated with high discontinuation rates, and warrant discussion beforehand.
Le texte complet de cet article est disponible en PDF.Key words : alopecia, basal cell carcinoma, dysgeusia, itraconazole, meta-analysis, muscle spasms, sonic hedgehog inhibitors, sonidegib, TAK-441, vismodegib
Abbreviations used : BCC, CBR, CI, CRR, laBCC, mBCC, ORR, PTCH, RCT, RECIST, SCC, SHH, SHHis, SMO
Plan
| Drs Xie and Lefrançois contributed to this work equally. |
|
| Funding sources: Partly supported by the Canadian Dermatology Foundation. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
Vol 79 - N° 6
P. 1089 - décembre 2018 Retour au numéro
Article précédent
- Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
- Jacob Siegel, Mariam Totonchy, William Damsky, Juliana Berk-Krauss, Frank Castiglione, Mario Sznol, Daniel P. Petrylak, Neal Fischbach, Sarah B. Goldberg, Roy H. Decker, Angeliki M. Stamatouli, Navid Hafez, Earl J. Glusac, Mary M. Tomayko, Jonathan S. Leventhal
- Second primary melanomas: Increased risk and decreased time to presentation in patients exposed to tanning beds
- Yang Li, Mukti Kulkarni, Kathryn Trinkaus, Lynn A. Cornelius
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?